Roivant Sciences Ltd.
ROIV
$11.92
$0.110.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -260.45M | 58.20M | 113.56M | 5.04B | 5.04B |
| Total Depreciation and Amortization | 11.21M | 12.16M | 17.79M | 18.36M | 18.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -279.24M | -543.38M | -521.74M | -5.53B | -5.53B |
| Change in Net Operating Assets | -55.72M | -99.62M | -118.15M | -43.85M | -43.85M |
| Cash from Operations | -584.20M | -572.65M | -508.54M | -511.74M | -708.17M |
| Capital Expenditure | -6.67M | -3.60M | -3.14M | -1.67M | -1.67M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 229.36M | 229.36M | 153.63M | 5.23B | 5.23B |
| Other Investing Activities | 219.86M | 1.30B | 309.55M | 8.08M | 8.08M |
| Cash from Investing | 442.55M | 1.53B | 460.04M | 5.24B | 5.20B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.09M | -50.92M | -58.59M | -17.16M | -17.16M |
| Issuance of Common Stock | 71.14M | 43.36M | 34.04M | 14.81M | 14.81M |
| Repurchase of Common Stock | -772.71M | -1.22B | -941.65M | -692.99M | -692.99M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.78M | 112.78M | 0.00 | 238.73M | 238.73M |
| Cash from Financing | -637.87M | -1.11B | -966.19M | -456.60M | -248.73M |
| Foreign Exchange rate Adjustments | -741.00K | -4.30M | -4.66M | -553.00K | -553.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -780.26M | -160.36M | -1.02B | 4.27B | 4.24B |